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Characterization of C-type natriuretic peptide receptors in human
mesangiat cells. Our aim was to examine whether the human glomerulus
was a target for C-type natriuretic peptide (CNP) and how A, B and C
receptors of natriuretic peptides (ANPR-A, ANPR-B, ANPR-C) were
distributed in glomerular mesangial and epithelial cells. CNP stimulated
cyclic GMP production in cultured human mesangial and epithelial cells
with similar threshold concentrations (1 nM) and maximum effects (basal
value X 30 at 1 M). In contrast, atrial natriuretic peptide (ANP) was only
stimulatory in epithelial cells. [1I] CNP bound specifically to mesangial
cells with a K, of 0.47 n and Bm,, of 42 fmol/mg. Equilibrium of binding
was obtained after four to five hours at +4°C and nonspecific binding
represented 10 to 20% of total binding. HS142-1 (100 .tWml), a specific
inhibitor of ANPR-A and ANPR-B, suppressed 90% of CNP-dependent
cyclic GMP production whereas it had little effect on ['I]-CNP binding,
suggesting that C receptors were largely predominant in mesangial cells.
No biological effect of CNP on mesangial cells, including change in basal
or angiotensin Il-induced contractility and inhibition of basal or serum-
dependent proliferation, could be demonstrated. Similar results were
obtained with 8-bromo-cyclic GMP and sodium nitroprusside. Intraglo-
merular localization of ANPR-A, ANPR-B and ANPR-C mRNA was
studied using reverse transcriptase-polymerase chain reaction with ampli-
fication of their corresponding cDNA by different primers. Amplification
products were identified on gel electrophoresis by their predicted sizes and
sequencing. ANPR-A, ANPR-B and ANPR-C mRNA were present in
epithelial cells whereas only ANPR-B and ANPR-C mRNA were detected
in mesangial cells. The presence of ANPR-C in both cell types was
confirmed by Northern blot analysis. This study indicates that human
mesangial cells, in contrast with epithelial cells, are not a target for ANP
whereas both cell types respond to CNP and possess clearance receptors.
The heterogeneity of receptors for atrial natriuretic peptide
(ANP) in murine and human glomeruli has been previously
demonstrated. Martin et al [1] reported that two-thirds of ANP
binding sites in rat glomeruli represented guanylate cyclase-
uncoupled ANP clearance receptors, whereas the remainder
corresponded to guanylate cyclase-coupled ANP receptors. The
localization of the latter within the rat glomerulus was thought to
be the mesangial cells since cultured mesangial cells produced
cyclic GMP in response to ANP [2]. We also found these two types
of ANP receptors in human glomerular cells, but with another
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distribution than in the rat. Clearance receptors were only ob-
served in cultured human mesangial cells, whereas both clearance
receptors and guanylate cyclase-coupled receptors were found in
cultured human glomerular epithelial cells [3, 4]. It is likely that in
vivo guanylate cyclase-coupled receptors are also localized in the
glomerular epithelial cells in the rat, since cyclic GMP was
detected only in these cells by immunofluorescence staining after
intravenous administration of ANP to the animals [5]. More
recently, three receptors for ANP have been identified in human
tissue, and cDNAs complementary to the mRNAs have been
cloned and sequenced [6—8]. ANP-A and -B receptors (ANPR-A,
ANPR-B) contain guanylate cyclase in their structure and thus are
responsible for the production of cyclic GMP, whereas ANP-C
receptors (ANPR-C) do not possess the guanylate cyclase domain
and correspond to the previously described clearance receptors.
ANP receptors can also be distinguished using pharmacological
tools because their affinity for various ANP analogues is different.
ANPR-A binds preferentially ANP but also binds brain natri-
uretic peptide (BNP). ANPR-B is activated selectively by C-type
natriuretic peptide (CNP). ANPR-C binds all three peptides and
also truncated analogues of ANP such as 4-23 C ANP which are
devoid of biological activity [9]. A recently described nonpeptide
ANP antagonist, HS-142-1, provides another mean to separate
ANPR-C from ANPR-A and -B because it blocks only the latter
two [10]. The issue may be still more complicated since Gunning
and Silva [11] have provided preliminary evidence for a CNP
receptor in the shark rectal gland which is distinct from ANPR-B.
It was initially thought that the ANPR-B were only found in the
central nervous system and were responsible for the central effects
attributed to the natriuretic peptides to control blood volume [12].
More recent studies demonstrated CNP binding sites and
ANPR-B mRNA in the kidney [13, 14]. In particular, Suga et al
[15] reported that human mesangial cells expressed ANPR-B but
not ANPR-A, thus confirming our previous finding that they do
not produce cyclic GMP in response to ANP [3].
The purpose of the present study was to address the following
questions: (1) How are ANPR-A, -B and -C receptors distributed
in human glomerular mesangial and epithelial cells? (2) What are
the characteristics of CNP binding sites and the biological effects
of CNP in human mesangial cells? To answer the first question,
we adopted a double approach including assessment of the cyclic
GMP response to the natriuretic peptides and cDNA amplifica-
tion with the polymerase chain reaction (PCR) to investigate the
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expression of the transcripts of the different natriuretic peptide
receptor subtypes.
Methods
Materials
The following radionuclides and reagents were obtained as indi-
cated: ANP-(1-28), C ANP-(4-23), human BNP-(1-32) (hBNP),
porcine BNP-(1-32) (pBNP), [Tyr°} CNP-(1-22), CNP-(1-22), and
angiotensin II (Asp1Ile5Ang II) from Peninsula Laboratories (Bel-
mont, California, USA); [1Ij-labeled [Tyr°] CNP-(1-22) (74 TBq/
mmol) from Centre d'Etudes Nucléaires Saclay (Gif-sur-Yvette,
France); ['I]-cyc1ic GMP (74 TBq/mmol) from New England
Nuclear (Boston, Massachusetts, USA); anti-cyclic GMP antibody
from Institut Pasteur (Paris, France); anti-vimentin antibody from
the Radiochemical Centre (Amersham, UK); Oligo-dT primer and
random primer from Promega (Madison, Wisconsin, USA); dNTPs
(2'-deoxynucleoside 5'-triphosphate) from Pharmacia LKB Biotech-
nology (Uppsala, Sweden); Moloney murine leukemia virus
(MMLV) reverse transcriptase from Gibco BRL (Cergy Pontoise,
France); Taq DNA polymerase from Perkin-Elmer (St-Quentin-en-
Yvelines, France); Sequenase version 2 DNA sequencing kit from
US Biochemical Corp. (Cleveland, Ohio, USA); [a355]-dATP (> 37
TBq/mmol) from the Radiochemical Centre; cell culture media and
cell culture supplies from Gibco BRL; and fetal calf serum (FCS)
from Boehringer (Mannheim, Germany). Oligonucleotide primers
(20 bases for each) specific for ANPR-A, -B and -C were synthesized
by Genset (Paris, France). HS-142-1, a nonpeptide natriuretic pep-
tide antagonist of microbial origin was a gift from Dr. Y. Matsuda
(Tokyo, Japan). All other reagents were from Sigma (St. Louis,
Missouri, USA).
Preparation of cells and characterization of natriuretic peptide
receptor proteins
Cell culture. Isolation and characterization of human glomeru-
lar mesangial and visceral epithelial cells were performed as
previously described [16]. Glomeruli were prepared from the
cortex of human cadaver kidneys judged to be unsuitable for
transplantation or from the intact pole of human kidneys removed
for circumscribed carcinoma. Glomerular cells were grown in
RPM! 1640 medium supplemented with glutamine (2 mmol/liter),
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)
(10 mmolJliter), penicillin (50 U/ml), streptomycin (50 g/ml),
and 10% FCS in an atmosphere of 5% CO2-95% air. Epithelial
and mesangial cells were purified by successive subcultures and
were studied after two to three and three to six passages,
respectively. They were identified routinely by light microscopy
and immunofluorescence staining. Epithelial cells are polyhedric
and grow in monolayers. They stain in the presence of an
antivimentin serum. Mesangial cells have a stellate appearance
and clump. They show a network of intracellular fibrils of myosin,
and they contract in the presence of 1 nmol/liter angiotensin II.
A simian virus-40 transformed human podocyte cell line was
also studied. These cells have been previously characterized and
shown to respond to ANP identically to the parental nontrans-
formed cells [17]. They were studied between the 20th and 30th
passages. Cells were cultured in a hormonally defined medium
(DMEM-HAM's F12, 1:1 vol/vol, supplemented with 2 mmol/liter
glutamine, 20 mmol/liter HEPES, 30 nmol/liter sodium selenate,
5 jsg/ml transferrin, 5 tg/ml insulin, 50 nmol/liter dexamethasone)
containing only 2% FCS. In most experiments, transformed
podocytes were used due to their greater availability and their
constant characteristics. Analysis of mRNA by PCR were per-
formed both in normal and transformed podocytes.
Determination of cyclic GMP production. Cells that were at
confluence in 12 well-plates were preincubated for 20 minutes at
37°C in RPM! 1640 medium without FCS containing 1 mmollliter
isobutylmethylxanthine (IBMX). The medium was aspirated and
cells were incubated during 10 minutes at 37°C with 0.5 ml of the
same medium containing CNP, ANP, hBNP or pBNP at final
concentrations between 10 pmol/liter and 1 jsmol/liter. Then, the
medium was collected and 0.5 ml of 0.1 M HCI was added to each
well for extraction of intracellular cyclic GMP. After 30 minutes at
4°C, extracts were pooled with their corresponding media and the
total cyclic GMP content was measured by radioimmunoassay
after acetylation of the samples and the standards using an
anti-cyclic GMP antiserum from Institut Pasteur (Paris, France)
and [125!] cyclic GMP as a tracer. The inhibitory effect of HS
142-1, a nonpeptide ANP antagonist, on the cyclic GMP response
was studied at concentrations between 1 and 100 gg/ml.
Binding studies. Mesangial cells in 24-well dishes that had
reached confluence were rinsed twice with serum-free medium
and were incubated in 0.25 ml of RPM! 1640 medium containing
2 mg/mI bovine serum albumin (BSA), 1 mmol/liter phenylmeth-
ylsulfonylfluoride, 2 mg/ml bacitracin and 10 mmol/liter HEPES
in the presence of [1I]-CNP at 4°C in room atmosphere during
six hours unless otherwise stated. At the end of the incubation
period, the medium was discarded and cells were rinsed four times
with 1 ml of ice-cold 0.16 at NaCI. Then, cells were solubilized with
1 at NaOH and cell-associated radioactivity was counted in a LKB
gamma automatic counter with 65% efficiency. Specific binding
was defined as the difference between total binding and nonspe-
cific binding obtained in the presence of unlabeled CNP. In
competitive inhibition studies, unlabeled CNP, C ANP-(4-23),
hBNP or pBNP were added at increasing concentrations (1
pmollliter to 1 itmolIliter). [1251]-CNP binding at equilibrium was
also studied in the presence of HS 142-1 at 100 gg/ml. Protein
concentration in each well was determined by the Bradford
method using BSA as a standard [18].
Identification of natriuretic peptide transcripts by reverse
transcription (RT)-polymerase chain reaction (PCR) and Northern
blot technique
RNA extraction and RT. Total RNA from cultured human
glomerular epithelial and mesangial cells was extracted by the
phenol-chloroform method and precipitated with 3 at LiCI as
previously described [19]. RNA concentration and purity were
determined from the A260 and A280 readings. Total RNA was then
reverse-transcripted to first strand cDNA with oligo-dT (15 mer)
and random primer (6 mer). The RT reaction was performed in a
mixture of 20 1d which contained: S jig of total cellular RNA, 0.5
mM of each dNTP, 1.5 jig of random primer, 1 jig of oligo-dT, 10
mat of dithiotreitol (DY!'), 1 X RT buffer (50 mat Tris-HCI, 15
mat KC1, 3 mrvi MgC12, pH 7.8) and 400 U of MMLV reverse
transcriptase. The RT mixture was incubated at 37°C during 60
minutes and the reaction was stopped by heating at 95°C for five
minutes.
PCR, One-fourth of the cDNA from the RT reaction was used
for amplification by PCR. Three pairs of primers specific for
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human ANPR-A, -B and -c cDNAs were designed from the
published sequences [6—8]. (1) ANPR-A, upstream 5'-AGGAC-
GAGTATGCGCTGACC-3' (nucleotides 489-508); downstream
5 '-GCCACCAGCTCTFGGGAAGT-3' (nucleotides 1328-1347).
(2) ANPR-B, upstream 5'-TGCCAGAACACAACI1TGAGC-3'
(nucleotides 375-394); downstream 5'-CCAGAGGGCCGCA-
GATATAC-3' (nucleotides 955-974). (3) ANPR-C, upstream
5'-GACATCGTGCGCAATATCCA-3' (nucleotides 736-755);
downstream, 5'-ATCCCCATATCGGTCTCCGT-3' (nucleotides
1226-1245). The sizes of the products between two primers are of
859 bp for ANPR-A, 600 bp for ANPR-B and 510 for ANPR-C,
respectively. PCR was carried out in a total volume of 100 d
which contained: 5 td of cDNA, 50 pmol of each of the primers,
0.5 m of each dNTP, 1 X PCR buffer (10 mi Tris-HCI, pH 8.3,
50 mM KCI and 3.5 mtvi MgCl2) and 2.5 U of Taq polymerase. The
reaction mixture was overlaid by mineral oil. Amplification was
carried out by 30 cycles of denaturation (94°C, 1 mm), annealing
(55°C, 1 mm) and extension (72°C, 2 mm) using a DNA thermo-
cycler. One-tenth of the PCR products was controlled by electro-
phoresis in a 0.9% agarose gel.
DNA sequencing. Each PCR product amplified from ANPR-A,
-B and -C cDNAs was purified by electrophoresis separation,
phenol-chloroform extraction and ethanol precipitation. Seven
microliters (6 to 13 ngIt.d) of each were taken directly for
sequencing by the dideoxynucleotide chain termination method of
Sanger, Nicklen and Coulson [20]. The sequencing extending
primers were the same as those of PCR for ANPR-A, -B and -C.
The sequencing reaction was performed as follows: purified DNA
(7 d) was annealed to 10 pmol of sequencing primer in a 10 d
reaction by heating to 98°C for six to eight minutes and cooling
directly on ice. Extension was carried out on ice for three minutes
using 0.5 jii (185 KBq) of a-35S-dATP, 1 d of 0.1 M DDT, 2 pi of
diluted (1:8) sequenase T7 DNA polymerase. A total of 3.5 i1 of
this reaction mixture was added to 2.5 tl of each termination
mixture and incubated for a further five minute period at 37°C.
The reaction was stopped by 4 t1 of formamide dye mixture. The
samples were electrophoresed in an 8% polyacrylamide, 7 M urea
sequencing gel, fixed, dried and exposed to X-ray film for one day.
Northern blot. The plasmid p GEM hANPR 4-2 containing the
entire human ANP C-receptor coding region was provided by Dr.
J. Gordon Porter of Scios Nova (Mountain View, California,
USA). This plasmid was cloned into the EcoRI site of the vector
p GEM 3 (SP6 orientation). The eDNA has been previously
described [7]. Total RNA from human mesangial cells (20 g per
lane) was fractionated by electrophoresis in agarose gel and
transferred to a nylon Gene Screen Plus membrane (New En-
gland Nuclear, Boston, Massachusetts, USA). After prehybridiza-
tion, the blot was hybridized for 16 hours at 42°C with the alpha
[32P] -labeled cDNA probe. The filter was then washed three times
at 42°C for 20 minutes in 2 X SSC (1 X SCC is 0.15 M NaCl and
0.015 M sodium citrate, pH 7.0) containing 0.1% SDS and exposed
to a Fuji X-ray film at —80°C in the presence of an intensifying
screen. The same filter was dehybridized by boiling for 15 minutes
in 0.1 SSC containing 1% SDS and rehybridized with a [32PJ-
labeled f3-actin eDNA probe.
Mesangial cell contractility
After removal of the culture medium, mesangial cells were
washed with RPM! 1640 medium containing 15 mmollliter
HEPES, pH 7.4 and 2 mmol/liter CaCI2. They were incubated in
the same medium for 10 minutes at 37°C. A first photograph was
taken as control. Then, the medium was replaced by an identical
medium to which the agent to be studied was added. Cells were
photographed again after 10, 20 and 30 minutes of treatment. The
mesangial planar surface area (average of 15 to 20 cells) was
quantified for each time point using a computerized image
analyzer as previously described [21]. Each cell served as its own
control.
Incorporation of [3H] thymidine in mesangial cells
Human mesangial cells were studied after they had reached
70% confluence in 12- or 24-well dishes. Cell growth was arrested
by 48 hour incubation in serum-free RPM! 1640 medium. The
resting cells were either maintained under the same conditions or
exposed to the standard medium plus 10% FCS with or without
the agent to be studied. Growth was assessed after 24 hours. [3H]
thymidine (0.5 pCi/well) was added six hours before harvesting.
At the end of incubation, the medium was discarded and the cells
were washed three times with 0.16 M NaCI containing 1 mivi CaCI2.
The cells were then exposed for 30 minutes at 4°C to 1 ml of 5%
trichloracetic acid. The medium was discarded and the cells were
dried and dissolved in 1 M NaOH. After pH adjustment to 7, the
3H radioactivity was measured by liquid scintillation spectroscopy
in a 1211 Rack-beta counter (LKB, Malmö, Sweden).
Statistics
Results are expressed as means sn. Comparisons between
groups were analyzed with the use of Student's t-test for paired or
unpaired values. Correlations between two parameters were esti-
mated by regression analysis.
Results
Distribution of ANP receptor in human glomerular mesangial and
epithelial cells
Cyclic GMP production. Mean basal cyclic GMP levels were 82.5
21.9 and 430 50 fmol/mg (mean SE; N 27) in epithelial
and mesangial cells, respectively. In epithelial cells, ANP, BNP
and CNP stimulated the production of cyclic GMP in a dose-
dependent manner (Fig. 1 left) with a threshold between 0.1 and
1 nmol/liter for the three peptides and increasing stimulations up
to 1 tmol/liter. At this concentration, cyclic GMP production was
52, 78 and 93 times higher than its basal value for ANP, BNP and
CNP, respectively. In mesangial cells, ANP and human BNP had
no effect on cyclic GMP production. Porcine BNP was also
inactive (0.27 and 0.16 pmol cyclic GMP/mg with 1 molIliter of
human and porcine BNP, respectively). In contrast, CNP was
markedly stimulatoiy. Cyclic GMP content reached 17 times its
basal value in the presence of 1 pmoWliter CNP (Fig. 1 right). No
plateau of cyclic GMP production was observed in both cell types
up to 1 mol/liter. HS-142-1, a novel competitive nonpeptide
ANP antagonist of microbial origin, reversed the stimulation by
ANP and CNP of cyclic GMP production in a concentration-
dependent manner (1 to 100 /Lg/ml; Table 1). Ninety percent of
CNP-stimulated cyclic GMP were inhibited by 100 tWml of HS
142-1 in both cell types. Fifty percent of ANP-stimulated cyclic
GMP were inhibited at the same concentration of this drug in
epithelial cells.
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RT-PCR identification of the ANPR-A, -B and -C transcripts.
cDNA samples corresponding to 1.2 jg total RNA from mesang-
ial or epithelial cells were subjected to 30 PCR cycles. cDNA from
NB-OK-i cells derived from a human neuroblastoma (a gift from
C. Delporte, Brussels, Belgium), which express only ANPR-A but
neither ANPR-B nor ANPR-C [22], were employed to control for
nonspecific amplification. As shown in Figure 2, epithelial cells
expressed cDNA sequences located between the two PCR-prim-
ers specific for each of the three classes of receptors. The PCR
products were of the expected lengths, 859 bp for ANPR-A, 600
bp for ANPR-B and 510 bp for ANPR-C. Similar results were
obtained with SV4O-transformed and nontransformed epithelial
HS4424
concentration
pg/mi
Epithelial cells Mesangial cells
CNPANP CNP
0 1181 126 3373 278 563 60
1 1102 103 2330 281° 350 93
10 748 41° 1272 98C 176 51°
100 628 48' 395 40° 22 11°
cells. cDNA from mesangial cells yielded the ANPR-B 600 bp and
the ANPR-C 510 bp amplification products. The signal for the
ANPR-A 859 bp amplification product was very faint. cDNA from
NB-OK-i cells yielded, as expected, only the ANPR-A 859 bp
amplification product (results not shown). In all these experi-
ments, there was no signal when the RNA was omitted during the
PCR amplification, which excludes contamination by genomic
DNA.
To further verify their specificity, the amplification products
were purified and sequenced. The sequences were identical to the
corresponding published DNA sequences of the human ANPR-A,
ANPR-B and ANPR-C genes.
Identification of ANPR-C mRNA by Northern blot technique. The
presence of specific ANPR-C transcript in human glomerular cells
was studied by Northern blot analysis using a human cDNA
probe. ANPR-C mRNA was detected both in epithelial and
mesangial cells. A predominant band of 4.8 kb just above the 28
S ribosomal band was detected. Figure 3 shows the presence of
this band when 20 jtg total RNA were deposited.
Characterization of CNP binding sites in mesangial cells
[1I]-CNP binding to mesangial cells was studied as a function
of time at 4°C at two concentrations (76 and 30 pmollliter) of the
labeled peptide. A plateau was reached after six to eight hours,
the most rapidly with the highest concentration (Fig. 4). Nonspe-
cific binding represented 10 to 20% of total binding at equilib-
rium. When human glomerular mesangial cells were incubated for
six hours with increasing concentrations of [1251]-CNP, the
amount of ['I]-CNP bound followed a curvilinear ascending line
(Fig. 5). Saturation of the binding sites was observed at 600 to 800
pmol/liter. The Scatchard plot of the data was linear, which
suggests the presence of one class of CNP binding sites. The
dissociation constant (Kd) and number of sites (Bmax) derived
from three such Scatchard analyses were 466 100 pmollliter and
41.9 4.9 fmol/mg protein (25,000 sites per cell), respectively.
HS-142-1 inhibited only a small fraction of [12511-CNP binding
to mesangial cells. Approximately 25% of the amount of [1I]
CNP bound to mesangial cells after six hours of incubation with 75
pmollliter of ['251]-CNP were inhibited in the presence of 100
g/ml of this antagonist.
When mesangial cells were incubated with 75 pmol/liter [125J]
CNP for six hours at 4°C in the presence of increasing concentra-
tions of unlabeled CNP (1 pmol/l to 0.1 mol/liter), competitive
displacement was observed. The inhibition curve decreased rap-
idly at the lowest concentrations of the competitor (<10 pmol/
A Table 1. Effect of HS-142-1 on CNP- or ANP-stimulated cyclic GMP
production (fmol/mg cell protein) in human glomerular cells
Means SE of 8 values (2 experiments) are shown. ANP and CNP
concentrations were 0.33 .mol/liter. Results were analyzed using Stu-
dent's t-test for unpaired values.
°P < 0.05; bp < 0.01; C < 0.001 against control
1O1 10° 10 10 10-v
M
8
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B
8
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Fig. 1. Cyclic GMP response of epithelial cells (A) ormesangial cells (B) to
increasing concentration of ANP (•), BNP (0) or CNP (x). Means sa of
9 values (3 experiments) are shown.
/
0
A B C A B C
Epithelial cells Mesangial cells
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Table 2. Effects of CNP and other agonists on human mesangial cell contractility
Treatment
Time mm
0 10 20 30
Batch 1
CNP 10806 943 10800 893 10770 901 10862 902
0.1 j.mol/liter (100) (99.9) (99.7) (100.5)
Ang II 11906 1008 10791 1029 9878 980 9273 940
0.1 mol/liter (100) (90.6) (83.0) (77.9)
CNP + Ang II 11353 1069
(100)
10565 1016
(93.0)
9686 978
(85.3)
9180 971
(80.9)
Batch 2
8-bromo-cGMP 6944 1040 6970 1057 6966 1056 7035 1063
0.1 mmol/liter (100) (100.4) (100.3) (101.3)
Sodium nitroprusside 7321 957 7084 945 7159 941 7116 939
0.1 mmol/liter (100) (96.8) (97.8) (97.2)
Ang II 5685 512 5402 494 5269 483 5134 486
0.1 imol/liter (100) (94.8) (92.6) (89.7)
8-bromo-cGMP 5949 443 5697 453 5614 467 5393 445
+ Ang II (100) (95.8) (94.4) (90.6)
Sodium nitroprusside 5398 471 4996 451 4838 450 4719 430
+ Ang II (100) (92.6) (89.6) (87.4)
Cell surface area (tim2) of 14 to 26 mesangial cells are given. The same cells from two batches corresponding to different kidneys were examined at
increasing time points under each experimental condition. Data were analyzed using Student's t-test for coupled values. The effects of Ang II and of
the combinations of Ang II with the various agents tested are significant (P < 0.00 1 versus zero time at each time point). There are no significant effect
with CNP, 8-bromo-cGMP or sodium nitroprusside when used alone.
Fig. 2. The PCR products obtained after
amplification of human glomerular epithelial and
mesangial cells cDNA. Amplification products
specific for the three receptor subtypes (ANPR-
A, -B and -C) were detected in epithelial cells.
With mesangial cells, similar yields of ANPR-B
and ANPR-C products were obtained, but the
signal for the ANPR-A product was at the limit
of detection. A DNA molecular weight ladder
is shown (left lane) for size comparison.
liter) but more slowly at higher concentrations. C ANP (4-23) was
also inhibitory but with a lesser affinity (Fig. 6). Concentrations
corresponding to 50% inhibition (ED50) were 1.8 and 100 pmol/
liter for CNP and C ANP (4-23), respectively. It is noteworthy that
the displacement of [1251]-CNP from mesangial cells was rapid at
low concentrations of unlabeled CNP, suggesting that a fraction of
the receptors in mesangial cells was of very high affinity. This
fraction which may correspond to the HS-142-1 sensitive ANPR-13
could not be distinguished from the predominant ANPR-C in
saturation binding studies. To clarify the responsiveness of the
CNP binding sites to BNP, we compared the inhibitory potencies
of hBNP and pBNP on [1251]-CNP binding to human mesangial
cells. Both peptides were equally potent with ED50 of 5.6 and 3.5
pmollliter, thus in the same range as that observed for CNP (Fig.
7).
Biological effects of CNP in mesangial cells
Mesangial cell contractility. Under control conditions, mesangial
cell average cross sectional area was in the range 5,500 to 13,000
.tm2. These values are in accordance with those previously
reported by Mené and Dunn [23]. We noted a variability in the
cell surface area of the cells obtained from different human
kidneys. Therefore, comparisons within the same preparations
were performed for analysis of the data (Table 2). Incubation of
a s —e
185 S
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mesangial cells in the culture medium under control conditions or
with addition of 0,1 mol/liter of CNP, 0.1 mmol/liter of 8-bromo-
cyclic GMP or 0.1 mmol/liter of sodium nitroprusside did not
result in significant changes of their planar surface areas within 30
minutes. In contrast, treatment by angiotensin II at 0.1 imollliter
resulted in contraction of about 50% of the cells with mean
surface reductions of 17 and 22.1% (P < 0.001) for cells from
batch 1, 7.4 and 10.3% (P < 0.001) for cells from batch 2 after 20
and 30 minute incubations, respectively. Treatment of mesangial
cells from batch 1 by angiotensin 11(0.1 j.mol/liter) and CNP (0.1
mol/liter) in combination did not modify the results obtained
with angiotensin II alone. Mean surface reductions were 14.7 and
19.1% after 20 and 30 minute incubations, respectively (P < 0.001
vs. time 0). Similarly, 8-bromo-cyclic GMP (1 mmol/liter) and
sodium nitroprusside (1 mmol/liter) were inactive on Ang II-
dependent mesangial cell contractility in cells from batch 2. Mean
surface reductions were 5.6 and 9.4% (P < 0.001) for the first
combination and 10.4 and 12.6% (P < 0.001) for the latter after
20 and 30 minute incubations, respectively.
3H thymidine incorporation. CNP (0.3 mol/liter) did not modify
[3H] thymidine incorporation in mesangial cells under resting
conditions (2467 761 vs. 2239 417 cpm per well) as well as
during multiplication (25804 7659 vs. 25105 7000 cpm).
Sodium nitroprusside (0.1 mM) and 8-bromo-cyclic GMP (0.5 mM)
were studied in the latter condition. Sodium nitroprusside was
inactive (19003 1345 vs. 18564 2115 cpm per well). There was
a trend toward inhibition with 8-bromo-cyclic GMP, but the level
of significance was not reached (14914 1406 cpm per well).
Discussion
The present data demonstrate that human mesangial cells are a
target for CNP. This assumption is based on the following
A
20
.
0 800Fig. 3. Northern blot analysis of total RNA from human glomerular me-
sangial cells (lane 1) and epithelial cells (lane 2) for expression of ANPR-C
and f3-actin inRNA. The positions of 28 S and 18 S ribosomal RNA bands
detected by ethidium bromide staining are shown.
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Fig. 4. Time-course of specific binding of [1I-Tyr°].CNP-(1-22) to human
glomerular mesangial cells at 4°C. Specific binding was measured at 2
different concentrations of [1251-Tyr°]-CNP-(1-22) in medium: (X) 76 pM;(•) 30 p. Means SE of 6 values (2 experiments) are shown.
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Fig. 5. Specific binding of ['251-Tyr°]-CNP-(1-22) to human glomerular
mesangial cells at equilibrium (6 hr) and at 4°C as a fl4nction of [I2SITyr0]
CNP-(1-22) concentration in medium. Means of 3 values are shown (top).
Scatchard transformation of the data (bottom) allowed the binding
parameters to be calculated: Kd = 641 pmol/liter, Bm = 45.3 fniol/mg.
Similar results were obtained in two additional studies.
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Fig. 7. Competitive inhibition of binding of [1251-Tyr°]-CNP-(1-22) to hu-
man glomerular mesangial cells at equilibrium (6 hr) and at 4°C in the
presence of increasing concentrations of unlabeled pBNP (•--•) and hBNP(0-0). Means SE of 9 values (3 experiments) are shown.
Suga et al [15] demonstrated that the ANPR-B receptor was
expressed in freshly prepared human kidneys and cultured human
mesangial cells, respectively. Concordance between in vivo and in
vitro data suggests that this characteristic of human mesangial
cells does not depend on a phenotypic change resulting from the
culture conditions. Circulating CNP immunoreactivity corre-
sponding to the 22-amino acid form of the peptide has been
detected in the dog [25] and in humans [26] at low picomolar
concentrations. The sites of CNP production are probably multi-
pie including the brain, kidney and intestines [27]. In particular,
Suzuki et al [28] demonstrated that both immunoreactive CNP
and CNP mRNA were present in an established cell line from a
normal rat kidney, whereas only immunoreactive ANP was found
exclusive of ANP mRNA. In addition, CNP immunoreactivity has
been found in human vascular endothelial cells [26] and human
monocytes [29].
Circulating or locally-formed CNP is responsible for essentially
vascular effects such as decrease in blood pressure [25, 30] and
inhibition of vascular smooth muscle cell proliferation [31, 32].
Smooth muscle cells are thus the main target of CNP. This
suggested that mesangial cells which possess most of their char-
acteristics could respond similarly to this peptide. Unexpectedly,
in the present study it was not possible to demonstrate any role of
CNP on mesangial cell contractility under control conditions as
well as in the presence of angiotensin II, the effect of which was
not inhibited. We also did not find any inhibitory effect of CNP on
mesangial cell growth both with resting and proliferating cells.
This differs from the results obtained by Porter et a! [31], who
showed that CNP inhibited serum- and growth factor-induced
DNA synthesis in bovine aortic smooth muscle cells via cyclic
GMP stimulation. Similarly, Furuya et al [32] observed an inhib-
itory effect of CNP on proliferation of cultured rat vascular
smooth muscle cells through an elevation of cyclic GMP. A
cell-permeant analogue of cyclic GMP, 8-bromo-cyclic GMP, and
an activator of the soluble guanlyate cyclase, sodium nitroprus-
side, also did not significantly modify angiotensin Il-dependent
contraction and serum-dependent proliferation of human me-
sangial cells. This could be due to the loss of expression of cyclic
0 1012 1 0-'° 1O 10
M
Fig. 6. Competitive inhibition of binding of ['251-Tyr°J-CNP-(1-22) to hu-
man glomerular mesangial cells at equilibrium (6 hr) and at 4°C in the
presence of increasing concentrations of unlabeled CNP-(1-22) (•-•) and C
ANP-(4-23) (0--). Means SE of 6 values (2 experiments) are shown.
grounds: (1) [1I]-CNP specifically binds to human mesangia!
cells with a high affinity (Kd = 466pmol/liter); (2) CNP stimulates
cyclic GMP production with a threshold dose of 100 pmol/liter;
(3) ANPR-B mRNA is expressed in mesangial cells, making it
likely that the same occurs for ANPR-B protein which is selec-
tively activated by CNP [12]. We have not shown unequivocally
that ANPR-B mediated the effects of CNP in human mesangial
cells. Such a demonstration would require a specific ANPR-B
antagonist which is still not available. However, the association of
[1I]-CNP specific binding sites, CNP-sensitive cyclic GMP re-
sponse and ANPR-B mRNA in mesangial cells suggests that this
assumption is correct. It is noteworthy, however, that the [125I]
CNP binding sites studied do not behave identically to the
ANPR-B present in human embryonic kidney cells and in COS-7
cells transfected with the ANPR-B expression plasmid [12}.
Indeed, both hBNP and pBNP similarly displaced [1251]-CNP
from its binding sites and little stimulated cGMP production in
human mesangial cells, whereas pBNP was more active than
hBNP in embryonic kidney cells and transfected COS-7 cells. The
difference in the binding data can be explained, in part, by the
presence of a majority of C receptors in human mesangial cells,
but the difference in cyclic GMP responsiveness possibly reflects
heterogeneity of the B receptor, as recently described by Gunning
and Silva [11].
Brown and Zuo [16], using in vitro autoradiography, reported
that [1I]-CNP reversibly bound to rat glomeruli exclusive of the
other parts of the kidney. In contrast with our results, CNP did not
stimulate cyclic GMP production in their preparation suggesting
the tracer was recognized by the ANPR-C, but not by the
ANPR-B subtype of natriuretic peptide receptors. Therefore, it is
likely that in the rat glomerulus CNP has no biological effect in the
absence of renal guanylate cyclase-coupled receptors for this
peptide. Our results suggest this is not the case in the human
glomerulus and raise the problem of the physiological role of
CNP. In agreement with our findings, Canaan-KUhl et al [13] and
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UMP-dependent protein kinase in passaged mesangial cells, as
shown previously in rat aortic smooth muscle cells by Lincoln,
Cornwell and Taylor [33]. Alternatively, a biological role for CNP
and its second messenger, cyclic GMP, in human mesangial cells
would have to be defined.
In contrast to mesangial cells, glomerular visceral epithelial
cells possess the two subtypes of ANP receptors linked to guany-
late cyclase (ANPR-A and ANPR-B). ANPR-A mRNA has been
already detected by RT-PCR in rat glomeruli with a large signal
similar to that observed in the terminal inner medullary collecting
duct [34]. But the intraglomerular localization could not be
determined. The present study shows that epithelial cells are a
target for CNP as well as for ANP. CNP, via cyclic GMP
production, could exert several effects. First, since increase in
cyclic GMP is associated in glomerular epithelial cells with
changes in the distribution of F-actin fibers [35], CNP could also
affect the arrangement of the foot processes and thereby the
permeability of the glomerular wall. Secondly, it is likely that, as
previously shown for ANP [36], the CNP-dependent cyclic GMP
release from the glomerular visceral epithelial cells takes place,
for its most part, on the apical side allowing a possible effect of
this nucleotide to occur downstream in the nephron. Further
studies are needed to characterize the CNP binding sites and
biological effects in human glomerular epithelial cells.
Mesangial and epithelial cells express ANPR-C as shown by
both RT-PCR and Northern blot analysis. This receptor predom-
inates in comparison with ANPR-A and ANPR-B. Since HS-142-1
only recognizes ANPR-A and ANPR-B [37], the fraction of
ANPR-C can be estimated by the part of [1I]-CNP binding sites
which is not inhibited by this antagonist, 75% in mesangial cells.
As expected, HS-142-1 inhibited 90% of CNP-stimulated cGMP
in both cell types. In contrast, it inhibited only 50% of ANP-
stimulated cyclic GMP in epithelial cells. The most likely expla-
nation is that HS-142-1 exhibits a higher affinity for ANPR-B than
for ANPR-A in our preparation. ['I]-CNP which recognizes
both ANPR-B and ANPR-C was, as expected, displaced from its
binding sites by CNP, hBNP, pBNP and C ANP (4-23), an
analogue specific of ANPR-C.
Thus we have shown that the human mesangial cells express
highly specific membrane receptors for CNP that are linked to
guanylate cyclase and that are not sensitive to stimulation by the
other natriuretic peptides. These CNP binding sites are likely to
represent both ANPR-B and ANPR-C as indicated by the results
of RT-PCR, the latter being predominant. In contrast, glomerular
epithelial cells possess the three subtypes of receptors for the
natriuretic peptide family: ANPR-A, -B and -C. Therefore both
cell types possessing ANPR-C are the site of natriuretic peptide
degradation. Epithelial cells produce cyclic GMP in response to
ANP and CNP whereas mesangial cells are sensitive only to CNP.
This suggests that cpithelial cells are the exclusive functional
target of circulating ANP. In contrast, it is likely that CNP behaves
as an autacoid in both cell types. Since the two peptides share the
same second messenger, cyclic GMP, their physiological specific-
ity in the glomerulus, which is still to be defined, must originate
from their target cell.
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